Drug Trial Radar · NCT03008187
MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Mar 10, 2017
Primary completion
Apr 13, 2023
Study completion Apr 13, 2023
Sponsor
- Lead sponsor
- Menarini GroupIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.; Theradex
- First posted
- Jan 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML).
Conditions
- Acute Myeloid Leukemia
Interventions
MEN1703Drug
MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and Part 2: Number of Participants Experiencing Treatment-emergent Adverse EventsTime frame: Up to 21 months
- Part 1: Number of Participants Experiencing Dose-limiting Toxicity (DLT)Time frame: Day 1 through Day 21 (first treatment cycle)
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Northside Hospital
Atlanta, Georgia
Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
Istituto Clinico Humanitas
Milan, Italy
ASST Monza - Ospedale San Gerardo
Monza, Italy
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Oddzial Hematologii z Pododdzialem Chemioterapi
Lodz, Poland
Institute of Haematology and Blood Transfusion
Warsaw, Poland
Institut Català d'Oncologia
Badalona, Spain
Hospital 12 de Octubre
Madrid, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.